Eliana F. R. Duraes

Eliana F. R. Duraes

Auto-generated profile, based on publicly available information

Eliana F. R. Duraes

Department of Plastic Surgery, Cleveland Clinic Foundation, Cleveland, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2022 in European Burn Journal
Verified
Journal Article
Open access
PDF file
JPJoseph S Puthumana
Joseph S Puthumana
EREmily Ross
Emily Ross
PKPatrick R. Keller
Patrick R. Keller
CDCarolyn S. Drogt
Carolyn S. Drogt
KKKimberly H Khoo
Kimberly H Khoo
SLSheera F. Lerman
Sheera F. Lerman
Burn survivors are at risk for dissatisfaction with body image, relationships, and sexuality due to disfiguring changes secondary to the injury. This review compares available global data on BSHS-B psychosocial scores. Twenty-four studies were included in the final analysis encompassing 14 countries; significant differences were found in scores across all BSHS-B psychological sub-sections of affect, body image, interpersonal relationships, and sexuality. On the whole, psychological well-being after burn injury was lower in Asian and South Asian countries compared to Europe or the United States. This study provides information for providers in burn centers caring for patients from a variety of cultural contexts and begins to steer initiatives to remedy psychological inequities in global burn care.

19 September 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Open access
PDF file
VAVictor F. A. Almeida
Victor F. A. Almeida
GDGlaudir Donato
Glaudir Donato
MDManoela Dantas
Manoela Dantas
EDEliana F. R. Duraes
Eliana F. R. Duraes
Background: Ketorolac, a nonsteroidal anti-inflammatory drug, is a promising opioid-sparing option for postoperative pain control. However, its impact on platelet function raises concerns about bleeding risk. Reduction mammaplasty carries a known risk of hematoma, and this study aimed to assess whether perioperative ketorolac increases this risk. Methods: We searched Cochrane Central, Embase, PubMed, and Web of Science databases for studies involving breast reduction patients who did or did not receive perioperative ketorolac. The primary outcome was hematoma formation, with secondary outcomes distinguishing between cases requiring surgery and those managed conservatively. A random-effects model calculated pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was assessed using the I 2 statistic. Results: Seven studies involving 3,418 patients were included—1991 in the ketorolac group and 1427 in the control group. The hematoma incidence was 6.13% in the ketorolac group versus 6.73% in controls. Meta-analysis revealed a significantly increased risk of hematoma in ketorolac users (OR 2.63, 95% CI 1.58–4.37, p < 0.001, I 2 = 37.5%), particularly in cases managed conservatively (OR 2.72, 95% CI 1.37–5.38, p = 0.004, I 2 = 26.3%). Sensitivity analysis reinforced these findings, also demonstrating an association between ketorolac and hematomas requiring reoperation. Conclusion: Perioperative ketorolac is associated with an increased risk of hematoma following breast reduction surgery. While it provides effective opioid-sparing analgesia, its use should be carefully considered, especially in patients with higher bleeding risks. Further randomized trials are needed to refine safety recommendations. Level of Evidence II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266

3 October 2025 in Microsurgery
Verified
Journal Article
Open access
VAVictor F. A. Almeida
Victor F. A. Almeida
GDGlaudir Donato
Glaudir Donato
ACAndressa Alves de Carvalho
Andressa Alves de Carvalho
WCWanessa Alves de Carvalho
Wanessa Alves de Carvalho
ALAmmar Lakda
Ammar Lakda
EDEliana F. R. Duraes
Eliana F. R. Duraes
Background: Autologous breast reconstruction using abdominally based flaps is common post‐mastectomy, but donor‐site pain often leads to prolonged opioid use. The transversus abdominis plane ( TAP ) block is a common regional anesthesia technique, with bupivacaine as the standard anesthetic. Liposomal bupivacaine ( LB ), a prolonged‐release formulation, aims to extend pain relief and reduce opioid consumption, though its efficacy remains debated. Objective: This systematic review and meta‐analysis compared LB versus plain bupivacaine ( PB ) in TAP blocks for autologous breast reconstruction, focusing on opioid consumption, pain scores, and hospital stay. Methods: A systematic search identified randomized controlled trials and observational studies comparing LB (with or without PB ) to PB in TAP blocks. Data were pooled using a random‐effects model ( I 2 ≥ 25%) or fixed‐effects model ( I 2 < 25%). Results: Six studies (429 patients) met inclusion criteria. LB was associated with significant reduction in opioid consumption on postoperative days ( POD ) 1 ( MD = −4.99 mg; 95% CI : [−8.42; −1.56], p < 0.01, I 2 = 0%) and POD 2 ( MD = −3.35 mg; 95% CI : [−5.74; −0.96], p < 0.01, I 2 = 0%). Pain scores were significantly lower on POD 2 and POD 3. No difference in hospital stay was found ( MD = −0.17; 95% CI : [−0.52; 0.18], p = 0.34, I 2 = 83.1%). Conclusion: LB reduced opioid consumption during the first 48 h postoperatively and modestly improved pain control on POD 2 and POD 3, but did not shorten hospital stay. Further large‐scale RCTs are needed to validate its benefits.

28 October 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
FSFanru Shen
Fanru Shen
DPDiwakar Phuyal
Diwakar Phuyal
BOBerk Baris Ozmen
Berk Baris Ozmen
VFVincent Ferrini
Vincent Ferrini
EDEliana F.R. Duraes
Eliana F.R. Duraes
RDRisal S. Djohan
Risal S. Djohan

29 December 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
VAVictor F. A. Almeida
Victor F. A. Almeida
GDGlaudir Donato
Glaudir Donato
MDManoela Dantas
Manoela Dantas
EDEliana F. R. Duraes
Eliana F. R. Duraes

3 June 2026 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Open access
JHJohn Yuxuan Ha
John Yuxuan Ha
VAVictor F.A. Almeida
Victor F.A. Almeida
FDFernando Ribeiro Duraes
Fernando Ribeiro Duraes
MDManoela Dantas
Manoela Dantas
DPDiwakar Phuyal
Diwakar Phuyal
EDEliana F.R. Duraes
Eliana F.R. Duraes
The impact of antidepressant use on surgical outcomes remains uncertain, particularly in breast reduction surgery, where risks of infection, wound complications, and bleeding may influence decision-making. To evaluate the association between preoperative antidepressant use and postoperative complications following breast reduction surgery. We performed a retrospective multicenter cohort study using the TriNetX Research Network. Adults who underwent bilateral breast reduction between 2010 and 2025 were stratified by recent antidepressant exposure. Propensity score matching balanced demographics, comorbidities, and laboratory values. Outcomes within 90 days included surgical-site infection, wound dehiscence, hematoma, seroma, sepsis, thromboembolism, composite complications, readmission, emergency-room visit, and opioid prescriptions. After matching, 7411 patients with antidepressant use were compared with 7411 controls. Antidepressant exposure was associated with increased risks of infection (5.1% vs. 4.1%; p = 0.006), wound dehiscence (4.1% vs. 2.8%; p < 0.001), and sepsis (0.4% vs. 0.2%; p = 0.031). Hematoma/seroma rates did not differ. Opioid prescribing was higher in antidepressant users (29.1% vs. 23.8%; p < 0.001). Class specific analyzes indicated that selective serotonin reuptake inhibitors carried a slightly higher risk than serotonin norepinephrine reuptake inhibitors. Patients with prescriptions for two or more antidepressants had higher rates of infection and overall complications than those on a single agent. Preoperative antidepressant exposure was associated with modest increases in infection, wound dehiscence, sepsis, and postoperative opioid prescribing after breast reduction surgery, whereas bleeding complications were not increased. These observational findings are hypothesis-generating and warrant further validation.